Decline depth
-33.8%
From rolling 252-day high of $47.65, 197d ago.
Past the 30% Amber threshold.
Amber ListRecovering
MLYSMineralys Therapeutics, Inc.
Healthcare · Biotechnology · small-cap ($1.9B)
-33.8%
from rolling 252-day high of $47.65 set 2025-11-12 · 197d ago
Current
$31.54
Decline depth
-33.8%
Decline σ
1.8σ
TFC
4/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since tracking began
$MLYS has been tracked since 2026-03-01. It was down 38.5% from its 52-week high then — now down -33.8%.
That's 11.9 percentage points deeper than the day it joined.
Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
MLYS qualifies for the Amber List on decline depth.
Time-frame continuity
4/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Past the 4/5 Amber threshold.
Decline sigma
1.8σ
Drop from local high over the last 5 bars, expressed in units of the stock's typical daily volatility (4.27% per day).
The structural read
What price action says about MLYS.
MLYS qualifies for the Amber List on decline depth — down -33.8% from its rolling 252-day high.
Cross-confirmation: also showing 4/5 bearish time frames.
Alongside that decline, our proprietary engine has flagged a confirmed bullish structural signal on one or more time frames — moderate or strong time-frame-continuity (TFC) alignment — so the ticker also carries a Recovering badge. The two readings coexist: the tier tells you how deep the damage is, the Recovering badge tells you whether momentum may be turning. Recovering is not a buy signal; it's a structural read.
Broken Stocks stops here — it flags the structure, it doesn't build the upside case. Working out whether MLYS's turn is investable is what our sister tool does: ConvictionEdge — triple-engine conviction research on names showing a recovery signal.
Upstream TFC read: strong alignment, current phase daily. Last bar types — daily 2U (green), weekly 2U (green), monthly 2U (green).
Earnings on file: 2026-03-12. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $10.44
56.7% of range
52W high $47.65
Sector context · Healthcare
194 other Healthcare tickers are on Broken Stocks.
89
Red List
46
Amber
59
Watch
-36.0%
Median decline
Worst in sector: OPRX (-77.1%). Least-bad: MRNA (-20.1%). See all Healthcare listings →
Related — same sector
Closest decliners to MLYS
Amber ListRecovering
AGIO
Agios Pharmaceuticals, Inc.
Amber List
ALHC
Alignment Healthcare, Inc.
Red List
MMSI
Merit Medical Systems, Inc.
Amber ListRecovering
STVN
Stevanato Group S.p.A.
Amber List
COLL
Collegium Pharmaceutical, Inc.
Red ListRecovering
VNDA
Vanda Pharmaceuticals Inc.
Questions about MLYS
What people ask.
Why is MLYS on Broken Stocks?
MLYS qualifies for the Amber List on decline depth. It is down -33.8% from its rolling 252-day high of $47.65, set on 2025-11-12 — 197d ago. It additionally carries a Recovering badge — see below.
What does the Recovering badge mean for MLYS?
Recovering means our proprietary engine has flagged a confirmed bullish structural signal on one or more time frames (moderate or strong time-frame continuity). It coexists with the decline tier — MLYS is still Amber List because the rolling-252-day decline hasn't healed, but a bullish setup has formed inside that decline. The two readings answer different questions: the tier tells you how deep the damage is; the Recovering badge tells you whether momentum may be turning. It's not a buy recommendation.
Is MLYS a falling knife?
Not by the strict technical definition. MLYS is down -33.8% from its 52-week high, but that high was set 197d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. MLYS is still on the Amber List for decline depth, but the freshness component of a falling knife is missing.
Is MLYS a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is MLYS trading inside its 52-week range?
At $31.54, MLYS sits 56.7% of the way from its 52-week low ($10.44) to its 52-week high ($47.65). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has MLYS been declining?
The current 33.8% decline accrued over 197d, which annualizes to roughly -62.6% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does MLYS compare to its sector?
There are 194 other Healthcare tickers on Broken Stocks: 89 Red, 46 Amber, 59 Watch, with 107 showing recovering structural signals. Median sector decline is -36.0% — MLYS's decline is shallower than the sector median.
Does MLYS's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-12) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.